Aclaris Therapeutics, Inc. (FRA:8AT)

Market Cap	297.96M +12.9%
Revenue (ttm)	13.42M -41.9%
Net Income	-120.75M
EPS	-1.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Average Volume	100
Open	2.662
Previous Close	2.727
Day's Range	2.662 - 2.662
52-Week Range	0.956 - 3.809
Beta	n/a
RSI	46.60
Earnings Date	Feb 27, 2026

About Aclaris Therapeutics

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JAK 1/3 inhibitor in Phase 2b trial for the treatmen...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 63
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8AT

Financial Performance

In 2024, Aclaris Therapeutics's revenue was $18.72 million, a decrease of -40.09% compared to the previous year's $31.25 million. Losses were -$132.07 million, 49.3% more than in 2023.

Financial numbers in USD